Item 2.02 Results of Operations and Financial Condition.

On January 13, 2021, Flexion Therapeutics, Inc. ("Flexion") issued a press release announcing certain preliminary financial results for the fourth quarter and year ended December 31, 2020, and made available on its corporate website a related presentation. A copy of the press release and the presentation are attached hereto as Exhibits 99.1 and 99.2, respectively.

The information in this Item 2.02 and Exhibits 99.1 and 99.2 hereto is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or the Exchange Act, or otherwise subject to the liabilities of that section.

Item 8.01 Other Events.

Flexion estimates that its net sales during the quarter and full year ended December 31, 2020, were $26.3 million and $85.5 million, respectively, and that its cash, cash equivalents, and marketable securities as of December 31, 2020, were approximately $175 million. This financial information is preliminary and subject to adjustment.

Item 9.01 Financial Statements and Exhibits.



(d)Exhibits.



Exhibit
 Number                                    Description
  99.1       Press Release of Flexion Therapeutics, Inc. dated January 13, 2021
  99.2       Presentation of Flexion Therapeutics, Inc. dated January 13, 2021
  104      Cover Page Interactive Data File (embedded within the Inline XBRL document)


                                       1

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses